ABSTRACT OBJECTIVES: The purpose of this study was to evaluate the prevalence of medication-related osteonecrosis of the jaw in Slovak population and compare the literature fi ndings, whether the prevalence of MRONJ is underestimated. BACKGROUND: Antiresorptive drugs signifi cantly increase quality of life, although during therapy, or in posttreatment period, osteonecrosis of the jaws might occur as a severe adverse effect. Medication-related osteonecrosis of the jaws (MRONJ) is a severe problem that has been observed in the past few years. METHODS: This multi-centric study evaluates the prevalence in Slovak population, assesses the values from 4 largest centres of maxillofacial surgery in Slovakia (1166 patients with MRONJ) and provides the comparison of literature review. RESULTS: Between 2010-2015, there was increasing number of newly diagnosed patients with MRONJ (1166 overall MRONJ patients) annually, except 2012 (mean growth of 123.88 %). This fi nding was supported by a statistical analysis of the rising tendency of prevalence in literature, where there was a signifi cant difference in prevalence of non-oncologic patients before and after 2010 t(15) = 2.725, p = 0.016. The 6-year prevalence was 1.34 % in population with antiresorptive drugs intake, for osteoporosis 0.47 %, for breast cancer 4.10 %, prostate cancer 3.99 % and multiple myeloma 21.26 %. CONCLUSION: This study considers that there is a signifi cant rising tendency of MRONJ in non-oncological patients, what could be caused by underestimation of the risk for development MRONJ in these patients. There should be a better cooperation and information among dentists and doctors indicating the antiresorptive treatment and strong emphasis on primary prevention before the initial treatment even in non-oncological patients (Tab. 5, Fig. 7, Ref. 69). Text in PDF www.elis.sk.
Introduction
Antiresorptive drugs (mainly bisphosphonates) are a group of medication widely used to inhibit bone loss by osteoporosis or as the agent against skeletal-related events as bone metastases in malignant disease (e.g. breast cancer, prostate cancer, lung, renal cancer and other organs) or in multiple myeloma, which has essentially a positive impact on quality of life (1, 2) . Bisphosphonates are poorly absorbed in the gastrointestinal tract and almost immediately the resorbed dose is taken up by bone from plasma with a high affi nity to bone hydroxyapatite (approximately half of resorbed dose), the rest is excreted by kidney in non-methabolised form. While the half-period of bisphosphonates in plasma is few hours, in the bone it is about 10 years (3) (4) (5) . There are many adverse effects of antiresorptive drugs described in literature, such as atrial fi brilation, over-suppression of bone turnover, hypocalciemia, acute infl ammatory response, severe musculoskeletal pain, esophageal irritation and erosion , but none has the attention of the osteonecrosis of the jaws (6) . Since the medication-related osteonecrosis of the jaw (MRONJ, also known as bisphosphonates-related osteonecrosis of the jaw BRONJ, osteonecrosis of the jaw ONJ, antiresorptive drugs-related osteonecrosis of the jaw ARONJ) was fi rst described by Marx in 2003 (7) as a severe side effect of antiresorptive drugs, the problem has been well monitored and welldescribed (8, 9). Determining the risk of developing the MRONJ is troublesome, however, intravenous application has a higher risk compared to per os administration used in non-malignant condi-tion (6, (10) (11) (12) (13) . The main factor for development of osteonecrosis is tooth extraction, followed by dental prosthesis irritation, periodontal and periapical disease, clinical fi ndings accompanied by any type of infl ammation (9, 14, 15) .
The defi nition of MRONJ was established by The American Association of Oral and Maxillofacial Surgeons (AAOMS) as an update of their defi nition of medication-related ONJ to:
• current or previous treatment with antiresorptive or antiangiogenic agents; • exposed bone or bone that can be probed through an intraoral or extraoral fi stula(e) in the maxillofacial region that has persisted for more than 8 weeks; and • no history of radiation therapy to the jaws or obvious metastatic disease to the jaws. The International Task Force on Osteonecrosis of the Jaw of the American Society for Bone and Mineral Research defi nes ONJ as:
• exposed bone in the maxillofacial region that does not heal within 8 weeks after identifi cation by a health care provider; • exposure to an antiresorptive agent; and • no history of radiation therapy to the craniofacial region (8, 9).
The purpose of this article is to estimate the prevalence and incidence of MRONJ in Slovak population from 4 largest centres and compare oncological vs. non-oncological group, with the focus on the non-oncological patients, who are potentially a large group of risk patients in dentoalveolar treatment due to persistence of bisphosphonates in the skeletal tissue for years, even if therapy of primary disease was successfully fi nished.
Materials and methods

Methods
The design of the study was established on medical data, which was collected from January 2010 to December 2015 in the 4 referral centres of maxillofacial surgery in Slovakia (Department of Stomatology and Maxillofacial Surgery, L. Pasteur University Hospital in Kosice; Department of Stomatology and Maxillofacial Surgery, Comenius University, Faculty of Medicine and St. Elisabeth Cancer Institute, Bratislava, Slovakia; Department for Oral Surgery, Jessenius Faculty of Medicine, Comenius University, Martin, Slovakia, Department of Oral and Maxillofacial Surgery, Comenius University, University hospital of Bratislava) from medical records of adult patients. Each centre sent the data, which consisted of primary diagnosis treated with antiresorptive medicaments, sex, year of fi rst visit (start of dispensarisation). Subsequently, the study assessed only the main oncological diagnoses and benign primary diagnose. The study included only the fi rst-time diagnosed MRONJ patients from 2010 to 2015, the recurrences were excepted, and the MRONJ were assessed according to the defi nition of AAOMS stage 0-III (9) , stages were not assessed in this study.
The data from medical records were compared yearly with an overall number of treated patients during years 2010-2015 and each other according to previous year for the assessment of an increasing or decreasing tendency of overall MRONJ occurrence. This comparison was also performed for the most frequent diagnoses (Fig. 1) .
The numbers of national disease data were extracted from the National health information centre publications, which has been upgraded and published yearly. The National health information centre (NHIC) is a state-funded organization founded by the Ministry of Health of the Slovakia, which performs tasks in the area of health statistics and provision of library and information services in the fi eld of medical sciences and health service. It administrates national health registries and national health administrative registries as well.
The patients were subsequently divided into 2 groups characterised by the primary disease, for which was the bisphosphonates therapy indicated. The study was focused on analysis of the prevalence in population, incidence of the disease in patients, who have undergone the antiresorptive treatment and the risk ratio for each of the most frequent diagnoses.
Results
These 4 largest regional centres covered approximately 72.29 % of Slovak population (from 8 total number of regions 6 regions were covered in this multi-centric study except 2). It represents the population of 3 919 821 (male population of 1 906 668, female 2 013 153) (16) . The total number of MRONJ group was 1166 patients (402 males -34.48 %, 764 females -65.52 %), which was divided to two study groups -oncological (819 patients -70.24 %) and non-oncological patients (347 patients -29.76 %). The number of patients in the oncological group was 819 (70.24 % of overall MRONJ) (Fig. 2) , in which 3 dominant diseases (670 patients) were evaluated more in detail. Multiple myeloma (156 patients, represent 13.38 % from overall numbers, 58 males (4.97 %) and 98 females (8.40 %)), breast carcinoma (316 females, 27.10 %), prostate carcinoma (198 males, 16.98 %), the rest of the patients (148 patients) were miscellaneous diagnoses like (kidney carcinoma, any types of lymphoma, etc.), which were not evaluated.
In the non-oncological group, MRONJ occurred in 348 patients. Osteoporosis (345 patients; 99.13 %), was absolutely dominant primary diagnosis in the non-oncological group represented by 348 patients (29.85 % of overall MRONJ), from whom 281 were females (83.62 %) and 64 males (16.38 %).
We extracted the numbers of 4 main diagnoses (multiple myeloma, breast carcinoma, prostate carcinoma, osteoporis) from NHIC publications, which were evaluated in this study and assessed the prevalence and incidence of MRONJ (Fig. 3) . The numbers of MRONJ for each diagnose were associated with the prevalence of the oncological diagnose in Slovak population to estimate the incidence of MRONJ and the risk of occurrence. The total number of oncological diagnoses was considered as the summary of the new cases during the period despite of the success of treatment because MRONJ can occur independently from the therapy.
Statistical analysis
Statistical analysis (t-test, χ 2 test, odds ratio and relative risk) was performed by SPSS v. 23 for Windows (SPSS Inc, Chicago, IL, USA). P values under 0.05 were considered signifi cant. The prevalence of MRONJ was calculated to the population of covered area in this study during 2010-2015, in this period the prevalence of MRONJ was 29.75 per 100 000. The incidence in our study was increased from 2.76 per 100 000 to 7.60 per 100 000 (Figs 4 and 5). Each year had increasing number of patients according to the newly diagnosed MRONJ, except for 2012. The female: male ratio was 1 : 9, with statistical difference between yearly occurrence of each sex in the study evaluated by t test t(10) = -2.7, p = 0.047 (Figs 6 and 7) .
The t test was performed for the evaluation of the theoretical increasing/decreasing incidence in population by the comparison of yearly incidence to incidence in the fi rst year of study. There was statistically a signifi cant positive difference in the incidence between the fi rst year of the study and subsequent years t(5) = 2.695, p = 0.043.
The relationship between the two groups was assessed. T-test revealed a signifi cantly higher number of patients in the oncological group compared to the non-oncological group t(10) = 3.34, p = 0.008. T test was performed to evaluate the raising ratio (number of patients compared to the fi rst year of the study) in oncological and non-oncological group, there was no signifi cant difference between yearly ratios of growth t(10) = 1.014, p = 0.334.
To identify the number of patients, who had undergone treatment by bisphosphonates, every health insurance company in Slovakia was inquired about the numbers of patients taking bisphosphonates in their evidence, however, only one insurance company answered. The answering company covers nearly quarter of all patients in Slovakia (27.92 % from all patients), but with younger (active) insured patients according to the data of the insurance company (17) . Antiresorptive drugs were used by 21 116 patients in 2013 and 21 300 in 2014 respectively. This represents the overall number of patients, who underwent bisphosphonates therapy in Slovakia of approximately 120 000, calculated from the proportion of the overall population and the compound of the patients in each insurance company. The portion of osteoporosis treated patients rose from 1.07 % in 2001 to 5.08 % in 2011, which represents about 100 340 patients. The most prescribed drugs were ibandronate, risedronate, aledronate,denosumab and strontium ranelate (18) .
To defi ne the risk of MRONJ, we calculated the prevalence of the main diseases in the study from publications of the National Cancer registry (19) (20) (21) (22) (23) (24) and the number of patients with osteoporosis in Slovakia (18). The yearly incidence was summed up during the last available years 2005-2010 (Tab. 1). However, it is necessary to realize, that the exact numbers of patients, who received the bisphosphonates or antiresorptive therapy in the following diagnoses is unknown. Because the bisphosphonates for intravenous administration are indicated in patients with symptomatic multiple myeloma, or in patients with skeletal-related events of primary cancer (estimate in 27) .
According to bisphosphonates administration in the covered population, the number of patients with bisphosphonates treatment was recalculated, the recalculation was made to the estimated higher percentage of bisphosphonates administration (Tab. 2).
Chi-square test showed a signifi cant relationship between MRONJ and oncological group χ There are many studies describing the prevalence of MRONJ. The articles to compare were included in the study according to the following criteria, available literature in English language, the keywords were "prevalence" , "risk", "bisphosphonate" and "osteonecrosis of the jaw" in Pubmed, Scopus and Medline and 1150 English language articles were found. The articles were divided to 3 categories -A -articles with oncologic and non-oncologic groups, B -oncologic groups only with the main diagnoses followed in this article, C -non-oncologic/ osteoporosis groups (Tab. 3). The articles assessed a risk of specifi c treatment (teeth extraction, endodontic treatment). For full text review, 6 articles were in A category, 14 in B category and in C category, there were 10 articles included. medicine fi rst authors and dental/ maxillofacial surgeon authors were assessed and provided. Based on the fi ndings of this study, the comparison, and statistical evaluation (t test) of the literature review was performed. The fi rst author was divided to general medicine and dental medicine group and the prevalence from the articles was compared for each category and main disease (Tab. 5). There was no signifi cant difference. Subsequently, the articles were also divided according to the year of investigation, one group contained articles until 2010 and the second group contained articles since 2011. There was a signifi cant difference of prevalence in non-oncological patients t(15) = 2.725, p = 0.016.
Discussion
Indications of antiresorptive treatment improves patient's quality of life, but MRONJ is one of the severe adverse effect of their administration (28), however, the positive effect is still predominant (29) (30) (31) . The risk of MRONJ development is increased by several factors, such as duration of BP therapy, administration route of BP, type of BP, invasive dental procedures or dental prostheses, oncological disease, caucasian origin and multiple myeloma (32) (33) (34) . The literature review shows much lower incidences and prevalence numbers than was described in this study, but on the other hand, it is possible to fi nd studies, where the numbers are very similar (35, 36). These studies were not included in literature review, because they were excluded in accordance with the literature review criteria. Some authors claim, that it is hard to defi ne the prevalence generally or exactly, because there is an estimated undiagnosed disease in population of approximately 25 %, mainly stage 0. (37) Therefore it is possible that the real number might be higher.
There were on average 2813 dental practices per year providing dental treatment in the observed period, which registered 4 153 908 adult patients. The percentage of preventive examinations was in average 53.01 % in adult patients. The average number of invasive interventions was 814 999 per year, which represents approximately one extraction in 5 adult patients per year, and given the number of removable dentures 91 680, 1 per 50 patients (38-42).
The data in this study imply, that there are approximately 120 000 patients in risk, taking antiresorptive treatment, where the oncologic to non-oncologic patient´s ratio is 1 : 5. Before, but also during the treatment, it is important to keep in mind the indication of antiresorptive treatment, whether it is due to malignancy or a benign condition.
Except for the primary cause and dental treatment there are co-factors of MRONJ mentioned in literature -namely the type of antiresorptive drug, its combination with immunosuppresive medication and the length of bisphosphonate treatment (43) . The MRONJ is also connected with the risk of atypical femoral fractures (44) .
It seems that the risk of MRONJ is higher in patients, who have been taking oral bisphosphonate for more than 5 years (45) . This would explain the rising number of patients, which is described in this study. Patients may not be treated by bisphosphonates any- more, but because of the pharmacodynamic characteristic of this group of medicaments, they are in high risk of MRONJ from the long term point of view due to long persistence of the drug in bones (3) (4) (5) . Probably this is the reason that the "patient's reserve" has been made and the MRONJ obtained even years lasting therapy without any complications. Therefore, it is of great importance to ask about patient's personal history in detail and to ask also about past drug history.
It is necessary that interdisciplinary of national societies gave a statement on this subject and defi ned the way of treatment of these patients and gave a guideline for patients within primary prevention (before treatment), but also during secondary (during bisphosphonate treatment) and tertiary prevention (after development of MRONJ).
The calculated risk of the development for MRONJ is 1 patient with MRONJ per one dental offi ce (during investigation period there were approximately 2800 dental offi ces in Slovakia) per 15 years in Slovakia. However, there are approximately 43 patients with risk per dental offi ce.
Conclusion
The fi ndings in this study showed an increasing tendency in numbers of MRONJ patients yearly, except for 2012, which was supported with the statistical analysis of comparison for older and newer literature. The study assessed that there were still significantly more oncological patients with MRONJ than non-oncological patients with 1.9 female: male ratio. The risk of MRONJ development is 10-times higher in the oncological group than in the non-oncological group, and the risk in multiple myeloma is 44-time higher than in non-oncological patients (Tab. 4). The 6-year estimated prevalence for the covered population in Slovakia was 0.47 % for osteoporosis, 3.99 % for prostate cancer, 4.10 % for breast cancer and 21.26 % for multiple myeloma. The data about antiresorptive drugs usage from insurance company showed that there could be decreasing numbers of patients, to whom the antiresorptive treatment was administrated. Unfortunately, in Slovak population, a preventive dental examination is done in about 53 % of adult population (38-42). According to the results in this study, primary prevention is strongly recommended before the start of antiresorptive treatment and preventive dental treatment should be more radical before an initial treatment in oncologic patients. It is necessary to investigate through medical and pharmacological history of the risk patients. 
